Search

Displaying results 5581 - 5590 of 7897 in total
  1. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    mutant mRNA sequence without affecting normal transcripts differing at even a single base pair. … Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative obtained from several plants, mainly Psoralea corylifolia.

    Products: Trisoralen Tab 5mg
  2. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.

  3. Drug

    BACTEK-R

    go.drugbank.com/drugs/DB16526
    Investigational

    MV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. These include streptococcus pneumoniae and staphylococcus aureus. Though stud...

  4. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  5. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  6. Drug

    Lutikizumab

    go.drugbank.com/drugs/DB16224
    Investigational

    Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).

    Synonyms: (synthetic human a-1234138 heavy chain), disulfide with synthetic human a-1234138 light chain, dimer
  7. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  8. Drug

    mRNA-3351

    go.drugbank.com/drugs/DB17718
    Experimental

    mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome

  9. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

  10. Drug

    EDI-200

    go.drugbank.com/drugs/DB18188
    Investigational

    EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

    Synonyms: FC:EDA-A1 FUSION PROTEIN, HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN